FDA warns Liveyon about selling unapproved stem-cell products that pose a risk to consumers

The Food and Drug Administration warned Livyeon for selling unapproved products derived from cord blood. It also also said "deviations" from best manufacturing practices could put consumers at risk.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news